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In a matched cohort study, we determined the death rates associated with drug resistance in Salmonella
Typhimurium. We linked data from the Danish Surveillance Registry for Enteric Pathogens with the Civil
Registration System and the Danish National Discharge Registry. By survival analysis, the 2-year death
rates were compared with a matched sample of the general Danish population, after the data were
adjusted for differences in comorbidity. In 2,047 patients with S. Typhimurium, 59 deaths were identified.
Patients with pansusceptible strains of S. Typhimurium were 2.3 times more likely to die 2 years after
infection than persons in the general Danish population. Patients infected with strains resistant to ampicil-
lin, chloramphenicol, streptomycin, sulfonamide, and tetracycline were 4.8 times (95% CI 2.2 to 10.2)
more likely to die, whereas quinolone resistance was associated with a mortality rate 10.3 times higher
than the general population.
oodborne  Salmonella infections have become a major
problem in most industrialized countries. Of particular
concern is the increasing number of infections with antimicro-
bial drug-resistant Salmonella, including the recent emergence
of drug-resistant Salmonella enterica serotype Typhimurium
(S.  Typhimurium) definitive phage type 104 (DT104). This
strain is usually resistant to at least five drugs: ampicillin,
chloramphenicol, streptomycin, sulfonamides, and tetracycline
(R-type ACSSuT) and has become a predominant Salmonella
type in many countries, including the United States, United
Kingdom, Germany, and France (1-4). In spite of its rapid
international dissemination (5) and the fact that antimicrobial
drug-resistant Salmonella was associated with human infec-
tions before the recent spread of DT104, the available data are
inconclusive regarding a possible increased virulence of
DT104. Whether antimicrobial drug resistance in DT104 con-
tributes to enhanced illness or death is unclear (5-7). Few stud-
ies have addressed the health impact of drug resistance in
types of zoonotic Salmonella other than DT104 (8-10), and
these studies suggest that drug resistance may be associated
with increased illness and death rates. 
Excess mortality associated with drug resistance in
zoonotic Salmonella is difficult to quantify. Death is a rela-
tively rare event and may not occur until months after the ini-
tial diagnosis. Furthermore, a number of factors, including
chronic and malignant diseases, may contribute to death from
salmonellosis. The objective of this study was to determine
death associated with antimicrobial drug resistance in S. Typh-
imurium. The study was based on a large, unbiased sample of
Danish patients registered in a national database. We linked
these data with those in the Danish civil registry, which has
complete information about survival status. Furthermore, by
completing the data with information from hospital discharge
registries, we were able to adjust for preexisting condition.
Materials and Methods
Surveillance
In Denmark the diagnosis of human Salmonella infections
is made at Statens Serum Institut (SSI) or at 10 clinical micro-
biology laboratories. The SSI receives notifications of positive
findings as well as isolates from the microbiology laboratories.
If a specific Salmonella serotype is found more than once from
the same person during a period of up to 6 months, only the
first positive sample is registered. As a part of this laboratory-
based surveillance system, monitoring for antimicrobial resis-
tance in S. Typhimurium was initiated in 1995. In 1995 and
1996, a sample of strains was tested, but from 1997 on, all S.
Typhimurium strains received at SSI were tested for antimi-
crobial susceptibility. This study included all isolates of S.
Typhimurium examined from January 1, 1995, through Octo-
ber 31, 1999.
Isolates were tested by tablet diffusion on Danish Blood
Agar (SSI Diagnostica, Hillerød, Denmark) with the use of
Rosco Neosensitabs (Rosco, Roskilde, Denmark). The panel
included 13 drugs from the Danish Integrated Antimicrobial
Resistance Monitoring and Research Programme (11).
Because reduced susceptibility to ciprofloxacin is difficult to
detect by the tablet diffusion test, the E-test (Biodisk, Solna,
Sweden) was used as well whenever the tablet diffusion test
identified nalidixic acid resistance. In this paper, quinolone
resistance refers to strains resistant to the first-generation qui-
nolone nalidixic acid (12). *Statens Serum Institut, Copenhagen, Denmark
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Registry Linkage Study
All live-born children and citizens of Denmark are
assigned a personal identification number, uniquely identify-
ing every person the Danish Civil Registration System (13).
Demographic data, including vital status, marriage status, emi-
gration/immigration, and address of residence, are kept in this
Civil Registration System. 
The matched cohort study used the data from the Civil
Registration System to compare the death rates of patients
with culture-confirmed S. Typhimurium infections to the death
rates of persons in the general Danish population. For each
patient, we randomly selected 10 people matched by age, sex,
and county of residence. People who were born during the
same month and year as the patient and were alive on the date
of sample receipt were eligible for the reference group. From
the Danish Civil Registration System, we obtained informa-
tion on vital status, date of change of vital status, (i.e., date of
death or emigration) and area of residence (county level) for
the patients and the persons included in the reference group. 
Data on admissions to hospital and discharge diagnosis
were obtained by using the data from the Danish National
Patient Registry (14) and the Cancer Registry for all persons
included in this study, thereby allowing us to control for preex-
isting illness (comorbidity). Danish National Patient Registry
contains data on all patients discharged from non-psychiatric
departments since January 1, 1977. Diagnoses and procedures
are coded according to the International Classification of Dis-
eases 8 or International Classification of Diseases 10 (from
1993). Diagnoses obtained during 10 years before infection
were used to calculate the comorbidity index.
Statistical Methods
The comorbidity index used the principles described by
Charlson et al. (15). This index is a sum of severity scores
(weights) corresponding to the number and severity of comor-
bidity conditions. In the first step, we analyzed the data from
the background population to calculate the relative rate associ-
ated with each of the diagnostic groups summarized in Table 1.
These relative rates served as the weights in the further sur-
vival analyses. The index was calculated by adding log-trans-
formed weights, thus taking into account multiple hospital
discharges. Diagnostic groups associated with a relative mor-
tality rate <1.2 were not included in the models. By including
this index in the survival analyses, any difference between the
death rates of Salmonella patients and the general population
quantifies excess mortality beyond what is attributable to
underlying illness. 
To compare mortality rates of S. Typhimurium patients
with those of  the general population, the data were stratified
so that each stratum contained 1 patient and 10 persons from
the reference group. To control for age, sex, and county of res-
idence, we used conditional proportional hazard regression.
Death up to 2 years after infection was determined, after
adjusting the data for comorbidity as described. To assess
death rates associated with antimicrobial drug resistance, inter-
action by drug resistance on Salmonella cases was determined.
We used the Wald test to test for homogeneity of the rate
ratios. The analyses were conducted by the use of the PHREG
procedure of the SAS system (Version 6.12, SAS Inst. Inc.,
Cary, NC). Death rate ratios (RR) are expressed as the relative
death rates of patients compared with the matched sample of
the general Danish population, and the term “referents” refers
to this unexposed matched sample. 
Results
Of 4,075 cases of S. Typhimurium infection reported in
Denmark from January 1995 to October 1999, the antimicro-
bial-drug susceptibility was determined in isolates from 2,059
cases, and a successful link to the Civil Registry System was
obtained for 2,047 (99.4%). In the period up to 2 years after
entry in the study, 59 deaths were identified in S. Typhimurium
patients and 221 deaths among 20,456 referents. The median
age of the 59 persons were 74.1 years (range 18.1 to 90.1). In
the first 30 days after entry in the study, the cumulative mortal-
ity proportion (Kaplan-Meier estimate) was 0.73% for S.
Typhimurium patients and 0.04% for the referents (RR 15.4,
95% confidence interval [CI] 6.1 to 39.2). In the period 30 to
720 days after entry, cumulative mortality was 2.75% in S.
Typhimurium patients and 1.51% in referents (RR 1.8, 95% CI
1.3 to 2.6). On this basis, we used the period 0 to 720 days in
the remaining analyses.
Overall, patients with S.  Typhimurium were 3.0 times
(95% CI 2.2 to 4.0) more likely to die than referents in the 2
years following infection. After the data were adjusted for
Table 1. The distribution of comorbidity diagnosis of 2,047 patients 
with S. Typhimurium infection and a sample of the general Danish 
population of 20,456 persons
Diagnostic group
No. (%) of S. 
Typhimurium 
patients
No. (%) in the 
general population
Severity score 
(weight) in 
comorbidity index
Lymphoma or 
leukemia
19 (0.9) 23 (0.1) 3.40
Metastatic cancers 8 (0.4) 19 (0.1) 2.02
Liver disease 10 (0.5) 35 (0.2) 1.97
Tuberculosis 0 13 (0.1) 1.78
Movement disor-
ders and epilepsy
4 (0.2) 40 (0.2) 1.56
Diabetes 44 (2.2) 186 (0.9) 1.50
Renal disease 31 (1.5) 114 (0.6) 1.37
Inflammatory 
bowel disease
39 (2.4) 66 (1.7) 1.34
Other neurologic 
diseasesa 
12 (0.6) 76 (0.4) 1.32
Hemoglobin 
abnormalities
14 (0.7) 62 (0.3) 1.23
Congestive heart 
failure
22 (1.1) 103 (0.5) 1.22
aNeurologic or neuromuscular diseases other than Alzheimer's disease, multiple sclero-
sis, Parkinson's disease, Huntington's disease, and epilepsy.RESEARCH
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comorbidity, the relative rate was 2.3 (95% CI 1.7 to 3.2). This
relative death rate was independent of age (p=0.84). 
A total of 631 (30.8%) patients were hospitalized in con-
nection with the S. Typhimurium infection. In the reference
group, 577 (2.8%) were hospitalized within 60 days of entry.
Five of those had gastroenteritis as their primary diagnosis.
Two hundred seventeen (10.6%) of S. Typhimurium
patients and 954 (4.7%) persons from the referent group had at
least one of the diagnoses listed in Table 1, which summarizes
the various diagnostic groups and their weights in relation to
the comorbidity index. A total of five HIV infections were
found, three among patients and two in the reference group.
All five were still living at the end of the study. 
In the 2,047 strains, 953 (46.6%) were pansusceptible,
1,094 (53.4%) resistant to at least one drug in the panel, and
639 (30.8%) were resistant to at least two drugs. Resistance to
sulfonamides was found in 47.3% of the patient isolates, tetra-
cycline in 25.1%, streptomycin in 22.4%, ampicillin in 19.2%,
chloramphenicol in 17.0%, kanamycin in 9.6%, quinolone in
4.1%, trimethoprim in 3.0%, gentamicin in 2.2%, and ceftri-
axon in 1.4%. No ciprofloxacin-resistant strains were found.
The MIC of ciprofloxacin in the quinolone-resistant isolates
ranged from 0.06 to 0.38 mg/L (median 0.09 mg/L). 
R-type ACSSuT was found in 283 (13.8%) isolates, and
patients infected with this type were 6.9 times more likely to
die than the general population, compared with a RR of 2.6 in
patients with strains of other R-types (p =0.02). Also, chloram-
phenicol (7.4 vs. 2.4, p=0.003), quinolones (9.9 vs. 2.8,
p=0.05), and ampicillin (5.1 vs. 2.7, p=0.09) were associated
with higher death rates in resistant than sensitive strains. 
Table 2 shows the relative death rate associated with anti-
microbial resistance after the data was adjusted for coexisting
diseases. Infections with pansusceptible strains were 2.3 times
(95% CI 1.5 to 3.5) more likely to die than the general popula-
tion, whereas infection with R-type ACSSuT was associated
with 4.8 times (95% CI 2.2 to 10.5) higher mortality. Patients
infected with quinolone-resistant strains (R-type Nx) were
10.3 times (95% CI 2.8 to 37.8) more likely to die, and R-type
ACSSuTNx was associated with 13.1 times (95% CI 3.3 to
51.9) higher mortality. Three other antimicrobial drugs (trime-
thoprim, gentamicin, and ceftriaxone) were examined, but
because of a low number of resistant strains, valid statistical
inference could not be carried out. All the strains resistant to
these drugs exhibited R-type ACSSuT. Most (82%) of the
chloramphenicol-resistant strains and 72% of the ampicillin-
resistant strains were also R-type ACSSuT. 
A total of 270 of the isolates with R-type ACSSuT were
phage-typed, and 217 (80.4%) were DT104, 18 (6.7%) DT12,
11 (4.1%) DT120, and the rest were other or unknown phage
types. Strains with other R-types were distributed over a num-
ber of different phage types. A total of 1,667 were examined,
and the three most common were DT12 (46.8%), DT66
(6.0%), and U288 (4.9%). Thirty-nine (2.3%) were DT104. In
the patients with R-type ACSSuT, no difference in the death
rate between persons infected with DT104 (relative death rate
4.4, 95% CI 1.7 to 11.6) and other phage types (relative death
rate 6.4, 95% CI 1.3 to 32.4) was found; both estimates were
adjusted for comorbidity.
No difference in age and sex distribution between patients
infected with R-type ACSSuT and other antibiograms were
found. The median age in both groups was 33 years (range 1 to
87 and 0 to 95, respectively, p=0.89).
Finally, we analyzed a model with three levels of resis-
tance: non-ACSSuT, R-type ACSSuT (Nx-sensitive), and R-
type ACSSuTNx. The figure shows the survival curve of the
referents and patients according to these three groups. In the
Table 2. Two-year relative death rate of patients infected with Salmonella Typhimurium, by antimicrobial susceptibility pattern. Registry linkage 
study including 2,047 patients and a random matched sample of 20,456 people from the Danish general population
Resistant Susceptiblea
Deaths/cases RRb (95% CIc) Deaths/cases RR (95% CI) p-valued
Resistant to >1 drug 31/1,094 2.4 (1.6–3.7) 28/953 2.3 (1.5-3.5) 0.86
Ampicillin 13/393 3.5 (1.7-7.2) 46/1,654 2.1 (1.5-3.0) 0.21
Chloramphenicol 16/347 5.1 (2.6-10.2) 43/1,700 1.9 (1.4-2.8) 0.01
Streptomycin 13/458 2.1 (1.1-4.1) 46/1,589 2.4 (1.7-3.4) 0.76
Sulfonamides 31/969 2.5 (1.6-3.9) 28/1,078 2.1 (1.4-3.3) 0.60
Tetracycline 15/513 2.2 (1.2-4.1) 44/1,534 2.4 (1.7-3.4) 0.85
Kanamycin 3/108 23/1,018 3.9 (2.2-6.7)
Quinolone 5/83 10.3(2.8-37.8) 54/1,964 2.1 (1.6-3.0) 0.02
R-type ACSSuT 12/283 4.8 (2.2-10.5) 47/1,764 2.1 (1.5-2.9) 0.06
R-type ACSSuTNx 5/40 13.1 (3.3-51.9) 7/243e 2.9 (1.1-7.9) 0.09
aSusceptible refers to strains susceptible to the given antimicrobial drugs or combination of antimicrobial drugs; first cell refers to pansusceptible strains.
 bDeath rate relative to the general population, as estimated by conditional proportional hazards regression analysis, controlling for underlying illness; RR=rate ratio.
cCI=confidence interval.
dp-value for test of homogeneity, i.e., RR for resistant being the same as for susceptible strains.
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group of 40 cases with R-type ACSSuTNx, we identified five
deaths within the 2-year period after infection, one of those
within the first month of infection, three within 6 months, and
one within 18 months. The relative risk associated with an
infection with R-type ACSSuTNx was 12.4 without adjusting
the data for comorbidity. After adjustment, the RR associated
with this resistance pattern was 13.1. The median age in this
group was 43 years (range 1 to 89), 10 years higher than the R-
type ACSSuT quinolone-sensitive group.
Discussion
Since the 1990s, the frequency of antimicrobial drug resis-
tance in zoonotic Salmonella and the number of drugs to
which the strains are resistant have increased, primarily as a
consequence of antimicrobial use in food production (1,9,16-
18). The recent development of fluoroquinolone resistance is
of particular concern (16-21). At present, a fluoroquinolone is
the drug of first choice for extraintestinal and serious intestinal
Salmonella  infections in adults, and resistance to this drug
may potentially reduce the efficacy of early empirical treat-
ment. The health impact of antimicrobial drug resistance in
zoonotic Salmonella needs to be determined (21,22). We used
data from registries created for other purposes to avoid bias
and were able to explore long-term death rates and adjust the
data for comorbidity. 
The comorbidity index was based on discharge diagnoses
from patients admitted to hospitals in Denmark and to a lesser
degree on data from outpatient clinics but did not include data
from general practitioners. Any patient with a coexisting dis-
ease severe enough to alter the outcome of a Salmonella infec-
tion is likely to have had contact with a hospital or an
outpatient clinic within the 10-year period before infection.
The backbone for the construction of the comorbidity index
was the National Discharge Registry. A validation of this
registry showed that there was agreement between the registry
and hospital records of 75% to 90%, using 3-digit level Inter-
national Classification of Diseases diagnoses (14).
In general, patients with S. Typhimurium infections were
2.3 times more likely to die than the matched sample of the
Danish population during a 2-year follow-up. This figure is
likely to reflect both long-term consequences of S. Typhimu-
rium as well as underlying diseases and conditions not fully
described by our comorbidity score based on hospital dis-
charge diagnosis. The excess mortality was independent of
age, a finding which warrants further studies. The cumulative
mortality in the first 30 days, 0.7%, is comparable with the
case-fatality rate of 0.8% for all nontyphoidal Salmonella sero-
types found in data from FoodNet 1996-97 (23).
We found that S. Typhimurium with R-type ACSSuT was
associated with higher death rates than other strains. Similar
tendencies were found for chloramphenicol and ampicillin,
both being markers for R-type ACSSuT. Patients infected with
R-type ACSSuT were seven times more likely to die than the
general population, but when the data were adjusted for under-
lying illness, this figure was reduced to fivefold higher mortal-
ity. This reduction was expected; a part of the excess mortality
associated with R-type ACSSuT was attributable to underlying
illness. However, the excess mortality still tended to be ele-
vated after adjustment. Patients with quinolone-resistant
strains had a marked and substantial excess mortality, which
could not be explained by imbalances in comorbidity. All the
quinolone-resistant strains in this study were designated as flu-
oroquinolone-susceptible by NCCLS cut-offs for ciprofloxa-
cin. Several patients in the study were part of an outbreak of S.
Typhimurium DT104 R-type ACSSuTNx traced back to swine
herds in the Danish island of Zealand (17).
Most deaths occurred in relation to infections with S.
Typhimurium DT104, and we were not able to demonstrate
any statistically significant variation among different phage
types. In our initial model, we took age into account, expecting
a relatively higher mortality among the elderly. But again, we
could not demonstrate such an effect. In other words, no addi-
tive effect was found between age and drug resistance com-
pared with age and being infected by sensitive strains of S.
Typhimurium. 
A study from England suggests that the isolation rates of
drug-resistant DT104 from blood cultures are not higher than
those of other S. Typhimurium phage types and that the fre-
quency is comparable with the incidence of blood culture iso-
lates of Salmonella Enteritidis (7). The study suggests that S.
Typhimurium of R-type ACSSuT does not cause invasive dis-
ease more often than Salmonella Enteritidis. However, the
overall mortality in relation to S. Typhimurium infection is
higher. Two studies based on outbreaks of resistant Salmonella
in the United States and the United Kingdom have found case
fatality rates of 4.2% and 3.0%, respectively (6,8). Even
though they were based on outbreak investigations, the cumu-
lative death rate is comparable to our results (2.9% after 6
months of infection). 
Figure. Survival comparison of patients infected with Salmonella Typh-
imurium (by resistance level) to referents. The patients and referents
were matched by age, gender, and county of residence.RESEARCH
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Antimicrobial drug resistance in zoonotic Salmonella may
be associated with adverse consequences in several ways,
including treatment failures. However, treatment failures have,
until now, been infrequently reported (17,21). We had no data
on treatment with antimicrobial drugs. Therefore, exploring
the extent to which the excess mortality of patients infected
with quinolone-resistant strains was caused by reduced effi-
cacy of drugs was impossible. We estimate that approximately
20% of the patients were prescribed empiric treatment in con-
nection with the collection of specimens and that some of the
deaths may have been associated with reduced efficacy of
flouroquinolones, as described in Mølbak et al. (17). 
Resistant bacteria have a selective advantage in ecosys-
tems where antimicrobial drugs are used. Studies have shown
that treatment with antimicrobial drugs (for any reason) is a
major risk factor for infections with antimicrobial drug-resis-
tant bacteria, and that this association may result in increased
incidence and illness severity (9,24,25). Infection with drug-
resistant S. Typhimurium in patients treated for other infec-
tions may contribute to the excess mortality we found. 
Infections with resistant Salmonella may be associated
with increased severity for reasons that are poorly understood.
An increased virulence of drug-resistant Salmonella has not
been well characterized. Two earlier studies found increased
rates of hospitalizations (10) and death (8), but these studies
had limitations. Lee et al. (10) were only able to control for
comorbidity in a limited way, and none of the earlier studies
were restricted to a single serotype and able explore the impact
of specific resistance patterns as we did. 
The use of antimicrobial drugs in food production is one of
the major factors in the emergence and dissemination of anti-
microbial drug-resistance in foodborne bacterial pathogens.
We were able to determine death rates in a large sample of
patients with S. Typhimurium and to control for confounding
factors in the analyses. We associated resistance in S. Typh-
imurium with excess mortality, and the demonstration of a
hazard to human health underscores the need for restrictions in
the use of antimicrobial drugs in the production of food from
animals. A particular risk was associated with quinolone resis-
tance, indicating that the use of fluoroquinolones for food pro-
duction animals should be discontinued. 
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